About
Certara delivers transformative drug development solutions by combining data-driven modeling, artificial intelligence, and predictive simulation across every phase of development—from discovery through market access. Its flagship AI platform, Certara.AI, is purpose-built for life sciences, enabling teams to integrate biological and pharmacological insights to optimize drug efficacy and safety predictions at scale. Key software products include Phoenix® for PK/PD and toxicokinetic modeling, Simcyp® for physiologically-based pharmacokinetic (PBPK) simulation in diverse patient populations, Pinnacle 21® for data standardization and regulatory submission validation, and CoAuthor™ for AI-assisted regulatory writing. The D360™ platform provides scientific informatics for molecule and bioactivity analysis, while GlobalSubmit™ streamlines eCTD regulatory submissions. Certara's services span modeling and simulation, biometrics and data science, regulatory and medical communications, real-world evidence, and market access strategy. Therapeutic centers of excellence cover oncology, pediatrics, rare diseases, and more. The platform is designed for pharmaceutical companies, biotech startups, and contract research organizations (CROs) seeking to reduce clinical trial risk, optimize dosing strategies, accelerate IND and NDA submissions, and demonstrate drug value to payers. Certara's Model-Informed Drug Development (MIDD) approach is recognized by regulatory agencies worldwide, making it an enterprise-grade solution trusted across the global drug development ecosystem.
Key Features
- Certara.AI Platform: A dedicated AI platform for life sciences that integrates pharmacological and biological data to optimize drug efficacy and safety predictions throughout development.
- PBPK Modeling with Simcyp®: Predict how drugs behave across diverse patient populations using advanced physiologically-based pharmacokinetic modeling and simulation.
- Regulatory Submission Tools: Pinnacle 21® and GlobalSubmit™ streamline data standardization, validation, and eCTD submission publishing to meet global regulatory standards.
- AI-Assisted Regulatory Writing: CoAuthor™ uses generative AI, structured templates, and content automation to accelerate the creation of regulatory documentation.
- Model-Informed Drug Development (MIDD): Integrated modeling and simulation services that inform dosing, safety, and efficacy decisions across all clinical development phases.
Use Cases
- Pharmaceutical companies using PBPK modeling with Simcyp® to predict drug behavior in pediatric or renally-impaired populations before clinical trials.
- Biotech teams leveraging Certara.AI and Phoenix® to analyze pharmacokinetic and pharmacodynamic data and determine optimal dosing strategies for first-in-human studies.
- Regulatory affairs groups using Pinnacle 21® and GlobalSubmit™ to validate, standardize, and submit NDA/BLA dossiers to the FDA and EMA.
- Medical writing teams accelerating the creation of regulatory documents and clinical study reports using CoAuthor™'s generative AI and structured templates.
- CROs providing model-informed drug development services to pharma clients, using Certara's integrated platform to deliver submission-ready biosimulation packages.
Pros
- End-to-End Coverage: Supports the entire drug development lifecycle from discovery and preclinical through late-stage clinical trials and market access in a single ecosystem.
- Regulatory Recognition: Certara's MIDD tools and methodologies are trusted and recognized by regulatory agencies worldwide, reducing submission risk.
- Specialized Life Sciences AI: Unlike general-purpose AI platforms, Certara.AI is purpose-built for pharmaceutical and biotech workflows with domain-specific intelligence.
Cons
- Enterprise Pricing: Certara's solutions are priced for large pharmaceutical and biotech organizations, making them cost-prohibitive for individual researchers or very early-stage startups.
- Steep Learning Curve: The breadth of tools and scientific complexity of biosimulation models require specialized training and expertise to use effectively.
Frequently Asked Questions
What is Certara.AI?
Certara.AI is the company's dedicated artificial intelligence platform designed specifically for life sciences, enabling organizations to integrate biological and pharmacological insights and optimize drug efficacy and safety predictions throughout the development process.
Who are Certara's primary customers?
Certara serves biotech companies, large pharmaceutical organizations, and contract research organizations (CROs) who need to accelerate drug development, reduce risk, and achieve regulatory success globally.
What is Model-Informed Drug Development (MIDD)?
MIDD is Certara's core approach to drug development, using predictive biosimulation and mathematical modeling to inform dosing, safety, and efficacy decisions—reducing reliance on costly and time-consuming trial-and-error methods.
What software does Certara offer?
Certara's software portfolio includes Phoenix® (PK/PD modeling), Simcyp® (PBPK simulation), Pinnacle 21® (data standardization), CoAuthor™ (AI regulatory writing), D360™ (scientific informatics), GlobalSubmit™ (eCTD submissions), and Certara.AI (the core AI platform).
Does Certara support non-animal testing approaches?
Yes, Certara offers Non-Animal Navigator™, a solution designed to help organizations navigate regulatory landscapes using alternative, model-based approaches that reduce or replace animal testing in drug development.
